Silver Book Fact

Effectiveness of an oral pharmacologic agent in preventing venous thrombosis

An oral pharmacologic agent has been demonstrated to be at least as effective as an injectable anticoagulant in the prevention of venous thrombosis following hip replacement.

Eriksson, BI, OE Dahl, N Rosencher, AA Kurth, CN van Dijk, SP Frostick, MH Prins, R Nettiarachchi, S Hantel, J Schnee, and HR Buller; for the RE-NOVATE Study Group. Dabigatran Etexilate Versus Enoxaparin for Prevention of Venous Thromboembolism After Total Hip- Replacement: A randomised, double-blind, non-inferiority trial. Lancet. 2007; 370(9591): 949-56. http://www.thelancet.com/journals/lancet/article/PIIS0140-6736%2807%2961445-7/fulltext

Reference

Title
Dabigatran Etexilate Versus Enoxaparin for Prevention of Venous Thromboembolism After Total Hip- Replacement: A randomised, double-blind, non-inferiority trial
Publication
Lancet
Publication Date
2007
Authors
Eriksson, BI, OE Dahl, N Rosencher, AA Kurth, CN van Dijk, SP Frostick, MH Prins, R Nettiarachchi, S Hantel, J Schnee, and HR Buller; for the RE-NOVATE Study Group
Volume & Issue
Volume 370, Issue 9591
Pages
949-56
URL
Read Full Resource

Categories

  • Innovative Medical Research
  • Human Value

Related Facts

  • Surgical Aortic Valve Replacements in 2010
    In 2010, ~67,500 surgical aortic valve replacements (SAVR) were performed in the U.S.  
  • Increased use of a blood-thinning drug prevents 40,000 strokes every year in the U.S.  
  • About 2/3 of reduced mortality from cardiovascular disease is a result of medical interventions.  
  • Over 1 million angioplasty-stent procedures are estimated to be performed each year in the U.S.  
  • If all forms of cardiovascular disease were eliminated, life expectancy would rise by close to 7 years.